Wang, Walter Z. http://orcid.org/0000-0003-1054-4688
Shilo, Konstantin
Amann, Joseph M.
Shulman, Alyssa
Hojjat-Farsangi, Mohammad http://orcid.org/0000-0002-0589-5523
Mellstedt, HÃ¥kan
Schultz, Johan
Croce, Carlo M.
Carbone, David P. http://orcid.org/0000-0003-3002-1921
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35CA197706)
Schnipke Family Endowment Fund to Support Clinical Trials and Cancer Research; the Robert and Martina Poe Small Cell Carcinoma Fund
Article History
Received: 30 July 2020
Revised: 12 May 2021
Accepted: 13 May 2021
First Online: 4 June 2021
Ethics statement
: This study was approved by the local IRB and The Ohio State University and followed the Declaration of Helsinki Ethical principle for Medical Research Involving Human Subjects. Written informed consent was obtained by all participants prior to inclusion in the study.
: Dr. Mellstedt reports grants from Kancera AB, personal fees from Kancera AB, outside the submitted work. Dr. Carbone reports personal fees from Abbvie, personal fees from Adaptimmune, personal fees from Agenus, personal fees from Amgen, personal fees from Ariad, personal fees from AstraZeneca, personal fees from Biocept, personal fees from Boehringer Ingelheim, grants and personal fees from Bristol Myers-Squibb, personal fees from Celgene, personal fees from Clovis, personal fees from Daiichi Sankyo Inc., personal fees from EMD Serono, personal fees from Foundation Medicine, personal fees from GenePlus, personal fees from Genentech/Roche, personal fees from Glaxo Smith Kline, personal fees from Gloria Bioscience, personal fees from Gritstone, personal fees from Guardant Health, personal fees from Helsinn, personal fees from Humana, personal fees from Incyte, personal fees from Inivata, personal fees from Inovio, personal fees from Janssen, personal fees from Kyowa Kirin, personal fees from Loxo Oncology, personal fees from Merck, personal fees from MSD, personal fees from Nexus Oncology, personal fees from Novartis, personal fees from Palobiofarma, personal fees from Pfizer, personal fees from prIME Oncology, personal fees from Stemcentrx, personal fees from Takeda Oncology, personal fees from Teva, outside the submitted work. The remaining others declare no competing interests.